Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | PRKDC | P78527 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1261676 | 0.87 | CA2 (0.52) | CA2CA4PRKDCMAPT | |
| SCHEMBL9058131 | 0.84 | CA2 (0.67) | CA2CA4PIK3CA | |
| SCHEMBL9058328 | 0.72 | CA2 (0.50) | CA2CA4 | |
| SCHEMBL8950397 | 0.67 | CA2 (1.00) | CA2CA4PIK3CA | |
| SCHEMBL32211602 | 0.66 | KMO (0.60) | PRKDCNPC1MAPTRAB9APIK3CA | |
| SCHEMBL226009 | 0.66 | KMO (0.60) | PRKDCNPC1MAPTRAB9APIK3CA | |
| SCHEMBL9057333 | 0.65 | CA2 (0.47) | CA2CA4 | |
| SCHEMBL20696085 | 0.65 | KMO (0.58) | PRKDCNPC1MAPTRAB9APIK3CA | |
| SCHEMBL3696631 | 0.64 | CA2 (0.40) | CA2CA4PRKDCPIK3CA | |
| SCHEMBL9058111 | 0.61 | CA2 (0.48) | CA2CA4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20080171750-A1 | Modulation Of Neurogenesis With Use of Modafinil | BRAINCELLS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167363-A1 | Modulation of Neurogenesis By Melatoninergic Agents | BRAINCELLS, INC (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080103105-A1 | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080064671-A1 | COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE | BRAINCELLS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-20070270449-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | CA2 1899/4885CA4 4247/4885PRKDC 1916/4885 |
| US-20080103105-A1 | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS | HMGCR, DCX, SREBF1 | CA2 4129/4885CA4 4641/4885PRKDC 2589/4885 |
| US-20070270449-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR5A, HTR6, GAP43 | CA2 4254/4885CA4 4831/4885PRKDC 2523/4885 |
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | PPARG, PPARA, PPARD | CA2 4424/4885CA4 4772/4885PRKDC 2173/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | CA2 1909/4885CA4 3445/4885PRKDC 1134/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | CA2 729/4885CA4 1416/4885PRKDC 4398/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | CA2 1562/4885CA4 3463/4885PRKDC 3780/4885 |
| US-20080064671-A1 | COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE | GRIN2C, COQ8A, GRIN2D | CA2 2390/4885CA4 3247/4885PRKDC 319/4885 |
| US-20080171750-A1 | Modulation Of Neurogenesis With Use of Modafinil | BDNF, DCX, NTRK2 | CA2 4417/4885CA4 4758/4885PRKDC 2037/4885 |
| US-20080167363-A1 | Modulation of Neurogenesis By Melatoninergic Agents | MTNR1A, GAP43, DCX | CA2 2621/4885CA4 3829/4885PRKDC 3632/4885 |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | CA2 897/4885CA4 2390/4885PRKDC 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.